NZ502626A - Vaccines comprising a nucleic acid vector encoding the G protein of respiratory syncytial virus (RSV) - Google Patents
Vaccines comprising a nucleic acid vector encoding the G protein of respiratory syncytial virus (RSV)Info
- Publication number
- NZ502626A NZ502626A NZ502626A NZ50262698A NZ502626A NZ 502626 A NZ502626 A NZ 502626A NZ 502626 A NZ502626 A NZ 502626A NZ 50262698 A NZ50262698 A NZ 50262698A NZ 502626 A NZ502626 A NZ 502626A
- Authority
- NZ
- New Zealand
- Prior art keywords
- nucleotide sequence
- rsv
- protein
- sequence
- promoter
- Prior art date
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title abstract 7
- 108091006027 G proteins Proteins 0.000 title abstract 4
- 102000030782 GTP binding Human genes 0.000 title abstract 4
- 108091000058 GTP-Binding Proteins 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 7
- 125000003729 nucleotide group Chemical group 0.000 abstract 7
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 229960000187 tissue plasminogen activator Drugs 0.000 abstract 1
- 238000011144 upstream manufacturing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
An immunogenic composition comprises a vector that cannot replicate in the respiratory tract of the host and a pharmaceutically acceptable carrier. The vector comprises a first nucleotide sequence encoding a RSV G protein, in which the transmembrane coding sequence and upstream sequence are absent, a promoter sequence operatively coupled to the first nucleotide sequence and a second nucleotide sequence located between the first nucleotide sequence and the promoter sequence. The composition generates protective antibodies to respiratory syncytial virus (RSV) G protein in the host. A vector, comprising a first nucleotide sequence encoding a RSV G protein and a promoter sequence operatively linked to the first nucleotide sequence, is used in the manufacture of a medicament that is suitable for immunizing against infection caused by RSV. The vector may further comprise a heterologous signal peptide encoding nucleotide sequence, wherein the signal peptide preferably encodes human tissue plasminogen activator. The promoter is preferably an immediate early cytomegalovirus promoter.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89644297A | 1997-07-18 | 1997-07-18 | |
| PCT/CA1998/000697 WO1999004010A1 (en) | 1997-07-18 | 1998-07-16 | Nucleic acid vaccines encoding g protein of respiratory syncytial virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ502626A true NZ502626A (en) | 2002-09-27 |
Family
ID=25406219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ502626A NZ502626A (en) | 1997-07-18 | 1998-07-16 | Vaccines comprising a nucleic acid vector encoding the G protein of respiratory syncytial virus (RSV) |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0996730A1 (en) |
| JP (1) | JP2001512662A (en) |
| CN (1) | CN1174099C (en) |
| AU (1) | AU756222B2 (en) |
| BR (1) | BR9815496A (en) |
| CA (1) | CA2296089A1 (en) |
| NZ (1) | NZ502626A (en) |
| WO (1) | WO1999004010A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083925A (en) * | 1995-06-07 | 2000-07-04 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| FR2790959B1 (en) * | 1999-03-15 | 2003-06-27 | Pf Medicament | USE OF BACTERIAL MEMBRANARY FRACTIONS WITH ADJUVANT EFFECT, THEIR PREPARATION METHODS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
| FR2798857B1 (en) * | 1999-09-23 | 2003-06-06 | Pf Medicament | USE OF AN OMPA MEMBRANE PROTEIN OF ENTEROBACTERIA ASSOCIATED WITH AN RSV IMMUNOGENIC PEPTIDE FOR THE PREPARATION OF NASAL ADMINISTRATIVE VACCINES |
| JP2004500366A (en) * | 1999-12-01 | 2004-01-08 | カイロン コーポレイション | Inducing specific antibodies for hepatitis C virus (HCV) |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| KR100938105B1 (en) * | 2007-09-21 | 2010-01-21 | 이화여자대학교 산학협력단 | Respiratory Synsichia Virus Vaccine |
| EA031177B1 (en) | 2008-07-16 | 2018-11-30 | Инститьют Фор Рисерч Ин Байомедисин | Human cytomegalovirus neutralizing antibodies and use thereof |
| KR101366702B1 (en) | 2010-10-21 | 2014-02-28 | 이화여자대학교 산학협력단 | Vaccine composition for respiratory syncytial virus and manufacturing method thereof |
| CN111303278B (en) * | 2013-04-15 | 2022-09-06 | 扬森疫苗与预防公司 | Human antibodies binding to RSV G protein |
| WO2021028787A1 (en) * | 2019-08-12 | 2021-02-18 | Advaccine (Suzhou) Biopharmaceuticals Co. Ltd. | Immune composition comprising respiratory syncytial virus (rsv) g polypeptide |
| WO2024139647A1 (en) * | 2022-12-26 | 2024-07-04 | 中国医学科学院基础医学研究所 | Human papillomavirus type 16 dna vaccine and use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
-
1998
- 1998-07-16 NZ NZ502626A patent/NZ502626A/en not_active IP Right Cessation
- 1998-07-16 WO PCT/CA1998/000697 patent/WO1999004010A1/en not_active Application Discontinuation
- 1998-07-16 JP JP2000503216A patent/JP2001512662A/en not_active Ceased
- 1998-07-16 AU AU84278/98A patent/AU756222B2/en not_active Ceased
- 1998-07-16 CA CA002296089A patent/CA2296089A1/en not_active Abandoned
- 1998-07-16 CN CNB988093014A patent/CN1174099C/en not_active Expired - Fee Related
- 1998-07-16 BR BR9815496-6A patent/BR9815496A/en not_active Application Discontinuation
- 1998-07-16 EP EP98934710A patent/EP0996730A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN1174099C (en) | 2004-11-03 |
| WO1999004010A1 (en) | 1999-01-28 |
| EP0996730A1 (en) | 2000-05-03 |
| BR9815496A (en) | 2001-12-18 |
| CA2296089A1 (en) | 1999-01-28 |
| AU756222B2 (en) | 2003-01-09 |
| AU8427898A (en) | 1999-02-10 |
| JP2001512662A (en) | 2001-08-28 |
| CN1271389A (en) | 2000-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6117696A (en) | Nucleic acid respiratory syncytial virus vaccines | |
| MXPA01008966A (en) | Nucleic acid respiratory syncytial virus vaccines. | |
| US5766602A (en) | Recombinant packaging defective Sindbis virus vaccines | |
| NZ502626A (en) | Vaccines comprising a nucleic acid vector encoding the G protein of respiratory syncytial virus (RSV) | |
| CA2259595A1 (en) | Dna immunization against chlamydia infection | |
| AU7075496A (en) | Neutralizing monoclonal antibodies to respiratory syncytial virus | |
| CA2228221A1 (en) | Papillomavirus polyprotein constructs | |
| ATE430200T1 (en) | VACCINE AGAINST THE VIRUS RESPONSIBLE FOR RESPIRATORY AND REPRODUCTIVE DISEASES IN SWINE | |
| NO20063711L (en) | Moraxella Catarrhali's outer membrane protein-106 polypeptide, gene sequence and uses thereof | |
| CA2193210A1 (en) | Method of inducing an immune response with a live venezuelan equine encephalitis virus expressing a heterologous immunogen | |
| CA2608864A1 (en) | Recombinant mva virus, and the use thereof | |
| DK1165791T3 (en) | Human cytokine as zalpha receptor ligand and its use | |
| CA2395499A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| NZ306483A (en) | Composition for inducing a mucosal immune response administered by two different routes | |
| CA2102208A1 (en) | Binding domains in notch and delta proteins | |
| RU98101249A (en) | OMR26 ANTIGEN HAEMOPHYLUS INFLUENZAE | |
| WO2004006952A3 (en) | Therapeutic tuberculosis vaccines | |
| BR9815642A (en) | Vector mutant DNA sequence, linear transcription of a vector's rna, composition and method for producing a respiratory syncytial virus RNA vaccine | |
| CA2305683A1 (en) | Immunogenic peptides from the hpv e7 protein | |
| AU4826493A (en) | Anti-feline immunodeficiency virus (fiv) vaccines | |
| Wolowczuk et al. | Protective immunity in mice vaccinated with the Schistosoma mansoni P-28-1 antigen. | |
| MXPA02005506A (en) | Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens. | |
| WO1997004099A3 (en) | Papillomaviruses, agents for detecting them and for treating diseases caused by such viruses | |
| EP0378929A3 (en) | Membrane proteins and peptides of haemophilus influenzae type b | |
| KR960702000A (en) | RECOMBINANT ANTIGENS FROM MUMPS VIRUS AND THEIR USE IN VACCINES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |
